In this week's edition...
 
— TODAY! Oregon Advocate Meeting: Drug Affordability Review Process Updates. See details below.
— Maryland Matters: It’s Time to Hit Pause on the PDAB. Click here to read the op-ed.
— Community Sign On Letter - IBX Policy Excluding Coverage for Rare Disease Products. See details below.
— Patient, Caregiver and Patient Advocate Self-Nominations Invited for PQA Health Plan Measure Concept Advisory Group. See details below.
— Payer Perspectives Confirm UPLs Will Likely Raise Costs and Hinder Patient Access to Medicines. Click here to read the survey.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. See details below.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
-- Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below.

In this week's edition...
 
— Oregon Advocate Meeting: Drug Affordability Review Process Updates. See details below.
— Payer Perspectives Confirm UPLs Will Likely Raise Costs and Hinder Patient Access to Medicines. Click here to read the survey.
— New PCORnet Data Report Provides Insights on Patient Populations Receiving Gene Therapy. Click here to read the report.
— CMS Public Engagement Events for Medicare Drug Negotiation Program. Click here to read the report.
— Use of QALYs and Similar Measures Deemed Acceptable in MD, Considered in Congress. See details below.
— The Protecting Health Care for All Patients Act Has No Budget Impact. See details below.
— CMS References ICER and NICE in Explanations for Medicare Drug Price Negotiation Program. See details below.
— ICHOM Conference and Activities Geared Up for 2025. See details below.
— Learn More About Alternative Measures for Value Assessment. Click here to learn more.
— Emerging Threats in States for Use of Discriminatory Metrics. See details below.
— What Happens in Countries Using QALYs and Cost-Based Thresholds? See details below.
— ICER's QALY-Based Study Topics. See details below.
— Upcoming Events and Webinars. See details below.
— AHRQ Effective Program Updates. See details below